Eli Lilly (LLY) CEO Dave Ricks said that the company will leave CAR-T therapies for cancer and gene therapies for rare diseases to others, as the company seeks deals to enhance its pipeline of future treatments, Reuters reports. “The data is amazing, but practically, it’s not reaching many people,” Ricks said of CAR-T therapy in an interview with Reuters. The comments come after the company announced an $8B purchase of Loxo Oncology (LOXO) this week, the report says
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.